Predicting the future of anti-tumor necrosis factor therapy by Verweij, C.L.
Available online http://arthritis-research.com/content/11/3/115
Page 1 of 2
(page number not for citation purposes)
Abstract
Tumor necrosis factor (TNF) antagonists are approved worldwide
for the treatment of rheumatoid arthritis (RA). Clinical experience
revealed that TNF-blocking therapy is effective for only approxi-
mately two thirds of patients, reflecting that there are ‘responders’
as well as ‘nonresponders’. Given the destructive nature of RA, the
risk of adverse effects, and considerable costs for therapy, there is
a strong need to make predictions on success before the start of
therapy. In the current issue of Arthritis Research & Therapy,
Hueber and colleagues become the first to present a multi-
parameter serum protein biomarker set that has predictive value
prior to the start of anti-TNF treatment. Ultimately, this finding may
contribute to a personalized form of medicine, whereby a specific
therapy will be applied that is best suited to an individual patient.
The concept of a personalized form of medicine has attracted
interest in the search for molecular and clinical criteria to
dissect anti-tumor necrosis factor (TNF) responders from
non-responders in rheumatoid arthritis (RA). Essentially, two
phases of unresponsiveness might be identified: a primary
phase directly after the start of treatment and a secondary
phase that develops in initial responders during the course of
therapy. The latter is explained by the formation of anti-drug
antibodies (anti-anti-TNF antibodies) in a subset of patients.
Efforts to understand differential responsiveness have
focused primarily on the mechanistic (that is, the primary)
phase of unresponsiveness. However, due to the temporal
aspects related to monitoring of the clinical response,
research findings from studies on the primary phase of
unresponsiveness might be intimately linked to processes
that are (also) related to anti-drug development.
The value of biomarker strategies in guiding clinical manage-
ment of monoclonal antibody (mAb) therapies has been
highly appreciated in the field of oncology. The perceived
importance and support for large-scale and well-powered
studies, such as gene expression profiling studies, in onco-
logy have been considerable and this may account for the
success in this field. For example, trastuzumab (Herceptin),
an anti-human epidermal growth factor receptor 2 (HER2)
mAb, is approved along with a diagnostic assay to select
breast cancer patients with a high likelihood to benefit from
therapy. However, such approaches have lagged behind in
the field of rheumatology.
It is to be expected that response prediction to TNF blockade
is a multifactorial event that requires a multiparameter bio-
marker. Accordingly, the research focus is multidisciplinary,
including clinometric, cytometric, metabonomic, genomic,
proteomic, and imaging approaches. Ideally, a molecular
biomarker signature as a predictor for anti-TNF responsive-
ness in RA should be obtained prior to the start of therapy in
a readily available biosample, such as peripheral blood (DNA,
RNA, protein, phenotypic cell markers, and/or metabolites),
although this compartment may not have direct implications
for our understanding of disease pathogenesis. In this issue
of Arthritis Research & Therapy, Hueber and colleagues [1]
report on a multiparameter serum protein biomarker set that
has predictive value.
Initial biomarker discovery approaches aimed to understand
the pharmacological effects of TNF blockade in the peripheral
blood compartment by pharmacogenomics for a comprehen-
sive understanding of the mode of action. These results
suggest that all patients treated revealed an overall similar
pharmacological response pattern, indicative of the presence
of bioactive TNF in the circulation irrespective of clinical
response [2,3]. Detailed analyses in search of (subtle)
differences in the pharmacogenomic response profiles
between responders and non-responders identified informa-
tive sets of genes whose expression changes during therapy
Editorial
Predicting the future of anti-tumor necrosis factor therapy
Cornelis L Verweij
Division of Inflammatory Disease Profiling, Department of Pathology and Rheumatology, VU University Medical Center, P.O. Box 7057, 1007MB
Amsterdam, The Netherlands
Corresponding author: Cornelis L Verweij, c.verweij@vumc.nl
Published: 22 June 2009 Arthritis Research & Therapy 2009, 11:115 (doi:10.1186/ar2724)
This article is online at http://arthritis-research.com/content/11/3/115
© 2009 BioMed Central Ltd
See related research by Hueber et al., http://arthritis-research.com/content/11/3/R76
ABCoN = Autoimmune Biomarkers Collaborative Network; ACR = American College of Rheumatology; IL = interleukin; mAb = monoclonal anti-
body; RA = rheumatoid arthritis; TNF = tumor necrosis factor.
Arthritis Research & Therapy    Vol 11 No 3 Verweij
Page 2 of 2
(page number not for citation purposes)
were associated with good clinical responses [4,5]. More-
over, baseline differences between responders and non-
responders were found [6]. Pharmacogenetic studies have
identified markers, including TNFA promoter polymorphisms,
associated with treatment outcome, although the predicting
capacity is weak and controversial findings were reported [7].
In the current issue of Arthritis Research & Therapy, Hueber
and colleagues [1] describe a multistep proteomics approach
to identify a serum protein biomarker set that has predictive
value prior to the start of etanercept treatment in population-
based RA patients. Their study is based on the premise of a
role for differential autoantibody specificities and serum
cytokine levels in guiding anti-TNF therapy. Therapy
responsiveness was assessed 3 months after the start of
therapy, based on the American College of Rheumatology
(ACR) criteria for improvement (greater than or equal to ACR
50% improvement criteria response). An integrated analysis
of a relevant set of 14 autoantibody specificities and a multi-
plex 12-cytokine Luminex data set in a combined set of 93
samples consisting of three independent cohorts (a US-
based Autoimmune Biomarkers Collaborative Network
[ABCoN] cohort [n = 29], a Swedish cohort [n = 43], and a
Japanese cohort [n = 21]) showed superior differentiation of
responders and non-responders. The autoantibodies were
significantly elevated and the trends for all analyzed
cytokines, such as TNF, interleukin-15 (IL-15), monocyte
chemoattractant protein-1 (MCP-1), and IL-6, revealed higher
baseline serum concentrations in responders, although the
latter lacked predictive value in itself. These results partly
corroborated findings reported by Fabre and colleagues [8].
Subsequent prediction analysis on the full sample set was
applied to select an integrated biomarker signature compri-
sing 13 autoantibody specificities and 11 cytokines that
enabled pretreatment classification of response in the three
ethnically diverse cohorts with a positive predictive value
ranging from 58% (Japanese cohort) to 71% (ABCoN
cohort). Although the overall prediction does not appear to be
that strong, further optimization and preselection of patients
on the basis of uniform disease-modifying anti-rheumatic drug
(DMARD) treatment regimens are likely to yield stronger
predictive values. These results suggest that patients with
features of an activated immune status in the peripheral blood
compartment are more likely to benefit from anti-TNF
treatment. Similar findings were reported for baseline synovial
tissue markers associated with responsiveness [9,10].
The identification of a proteomic biomarker in this work is an
important further step in the direction of response prediction
in RA and in the design of a multidisciplinary biomarker set
that takes in account the multifactorial nature of the response
prediction. The results of this and other biomarker studies
look promising, but full confirmation of the biomarker profiles
in independent uniform cohorts is of the utmost importance to
guarantee their validity to create added value for prediction of
the anti-TNF response in the general patient population.
Moreover, the true value of independent and combinatorial
biomarker sets can be tested in a prospective setting only.
Therefore, combined efforts between different research groups
and standardized clinical response measures and techno-
logical procedures to facilitate testing of multiple markers in
huge well-characterized prospective and well-powered
studies are essential and will bring the goal of personalized
and optimized anti-TNF treatment in RA within reach.
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